| 06:09a | ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs.. | |
| 01/18 | Morgan Stanley Lowers Price Target for Gilead Sciences to $72 From $74, Maintains Equal.. | MT |
| 01/06 | Morgan Stanley Downgrades Gilead Sciences to Equalweight From Overweight, Cuts Price Ta.. | MT |
| 01/06 | RBC Lifts Price Target on Gilead Sciences to $87 From $86, Maintains Outperform Rating | MT |
| 01/06 | ANALYST RECOMMENDATIONS : Bank of America, Dollar General, Evercore, Reckitt Benckiser, Un.. | |
| 2021 | ANALYST RECOMMENDATIONS : Biogen, Eli Lilly, Microsoft, Tesla, Weibo | |
| 2021 | Wells Fargo Starts Gilead Sciences at Equalweight With $72 Price Target | MT |
| 2021 | Goldman Sachs Starts Gilead Sciences at Neutral With $80 Price Target | MT |
| 2021 | Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to.. | MT |
| 2021 | Piper Sandler Initiates Coverage of Gilead Sciences With Neutral Rating, $77 Price Targ.. | MT |
| 2021 | BMO Upgrades Gilead Sciences to Outperform From Market Perform, Sets $85 Price Target | MT |
| 2021 | SVB Leerink Adjusts Gilead Sciences' Price Target to $75 from $77, Keeps Outperform Rat.. | MT |
| 2021 | GILEAD SCIENCES : Morgan Stanley Adjusts Gilead Sciences PT to $84 from $83, Keeps Overwei.. | MT |
| 2021 | GILEAD SCIENCES : RBC Boosts Price Target on Gilead Sciences to $86 From $84, Maintains Ou.. | MT |
| 2021 | GILEAD SCIENCES : UBS Adjusts Gilead Sciences' Price Target to $68 From $64, Maintains Neu.. | MT |
| 2021 | GILEAD SCIENCES : SVB Leerink Adjusts Price Target on Gilead Sciences to $77 From $74, Mai.. | MT |
| 2021 | GILEAD SCIENCES : BMO Capital Adjusts Gilead Sciences' Price Target to $72 From $67, Maint.. | MT |
| 2021 | GILEAD SCIENCES : RBC Boosts Price Target on Gilead Sciences to $84 From $81, Maintains Ou.. | MT |
| 2021 | ANALYST RECOMMENDATIONS : Amazon, Barclays, Comcast, Next, Pfizer... | |
| 2021 | GILEAD SCIENCES : RBC Capital Adjusts Gilead Sciences PT to $81 From $82 Expecting a Q2 Mi.. | MT |
| 2021 | GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83 From $81, .. | MT |
| 2021 | GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $81 From $87, .. | MT |
| 2021 | GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $69 from $65, Kee.. | MT |
| 2021 | GILEAD SCIENCES : RBC Capital Adjusts Price Target on Gilead Sciences to $82 From $80, Kee.. | MT |
| 2021 | GILEAD SCIENCES : Bernstein Upgrades Gilead Sciences to Outperform Rating From Market Perf.. | MT |
| 2021 | GILEAD SCIENCES : Redburn Upgrades Gilead Sciences to Buy From Neutral | MT |
| 2021 | GILEAD SCIENCES : SVB Leerink Adjusts Gilead Sciences' Price Target to $72 From $73, Keeps.. | MT |
| 2021 | GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $66 from $65, Kee.. | MT |
| 2021 | GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $87 From $83, .. | MT |
| 2021 | GILEAD SCIENCES : Morgan Stanley Upgrades Gilead Sciences to Overweight From Equal-Weight;.. | MT |
| 2020 | GILEAD SCIENCES : Truist Adjusts Price Target on Gilead Sciences to $62 From $67, Reiterat.. | MT |
| 2020 | GILEAD SCIENCES : Oppenheimer Adjusts Gilead Sciences PT to $100 From $105, Maintains Outp.. | MT |
| 2020 | GILEAD SCIENCES : BMO Capital Adjusts Gilead Sciences PT to $62 From $64, Maintains Market.. | MT |
| 2020 | GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $65 From $70, Kee.. | MT |
| 2020 | GILEAD SCIENCES : Redburn Reinstates Gilead Sciences at Neutral | MT |
| 2020 | PFIZER, GILEAD, ROSS : What to Watch When the Stock Market Opens Today | DJ |
| 2020 | Pfizer Says Covid Vaccine Is 95% Effective in Final Data, Will Seek Authorization | DJ |
| 2020 | Pfizer's Covid-19 Vaccine 95% Effective in Final Results, Company to Seek Approval With.. | DJ |
| 2020 | GILEAD SCIENCES : Morgan Stanley Reinstates Gilead Sciences at Equal-Weight With $67 Price.. | MT |
| 2020 | GILEAD SCIENCES : remdesivir gets U.S. FDA approval for hospitalized COVID-19 patients | RE |
| 2020 | Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug | DJ |
| 2020 | SPECIAL REPORT : Big Pharma wages stealth war on drug price watchdog | RE |
| 2020 | U.S. Stock Futures Pause After S&P 500's Record Close | DJ |
| 2020 | U.S. Stock Futures Edge Up After S&P 500's Record Close | DJ |
| 2020 | U.S. Stock Futures Edge Up After S&P 500's Record Close | DJ |
| 2020 | Hikma shares jump after improved sales outlook, COVID-19 drug deal | RE |
| 2020 | Hikma shares jump after improved sales outlook, COVID-19 drug deal | RE |
| 2020 | U.S. companies seeking capital during pandemic test bank market's new normal | RE |
| 2020 | GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 7th Updat.. | DJ |
| 2020 | GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 6th Updat.. | DJ |
| 2020 | GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 5th Updat.. | DJ |
| 2020 | GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient -- 4th Updat.. | DJ |
| 2020 | GILEAD SCIENCES : DZ Bank reaffirms its Buy rating | MD |
| 2020 | GILEAD'S REMDESIVIR COULD SEE $7 BIL : analyst | RE |
| 2020 | GSK's long-acting injection beats Truvada in HIV prevention trial | RE |
| 2020 | Gilead disputes report that its drug flopped in leaked coronavirus trial | RE |
| 2020 | Stock market gains alongside economic pain; some worry about over-optimism | RE |
| 2020 | Report says COVID-19 patients respond to Gilead's remdesivir, shares surge | RE |
| 2020 | Drugmakers see long road ahead in coronavirus vaccine race | RE |
| 2019 | Gilead invests $5 billion to deepen ties with biotech Galapagos | RE |
| 2019 | Gilead invests $5 billion to deepen ties with biotech Galapagos | RE |
| 2018 | Galapagos, Gilead bask in $4-6 billion new drug sales hope | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | FTSE slides after BOE meeting as pound pops higher | RE |
| 2017 | Gilead and GSK go head-to-head with similar HIV drug data | RE |
| 2017 | Gilead challenges GSK with strong HIV drug data | RE |
| 2015 | ABBVIE : revenue miss raises concerns over Humira sales | RE |
| 2015 | Wall St. ends lower with oil prices, renewed Greece worries | RE |
| 2014 | Irish tax changes may cost U.S. groups billions | RE |
| 2013 | Fast-growing Humira extends domination of AbbVie | RE |
| 2013 | Europe backs new dual-action Novartis lung drug | RE |
| 2013 | Factbox - U.S. biotech shares outpace broader stock market | RE |
| 2009 | GILEAD SCIENCES : Gilead profit rises a higher-than-expected 21 percent | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
